CombiGene strikes deal with Spark Therapeutics

CombiGene has entered into an exclusive collaboration and licensing agreement with Spark Therapeutics regarding CG01, CombiGene’s gene therapy developed for the treatment of drug-resistant focal epilepsy. Under the terms of the agreement, CombiGene is eligible to receive up to 328.5 million USD excluding royalties, with 8.5 million USD upon signing, as well as up to 50 million USD at several preclinical and clinical milestones.